Market Price

32.09 

-0.49 -1.5%

as of Jun 18 '21

52 Week Range:

17.20 34.29


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) -1.85
0.39
1.88
0.31
1.54
2.23
2.82
4.90
8.07
10.61
13.41
growth rate 100.0% 382.1% -83.5% 396.8% 44.8% 26.5% 73.8% 64.7% 31.5% 26.4%
Earnings BIT -39.47
-39.47
-46.28
-92.27
-5.28
20.84
54.22
99.54
144.44
150.27
188.10
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 160.1% 83.6% 45.1% 4.0% 25.2%
Avg.PE -3.60
-2.72
36.78
62.60
16.42
36.21
19.27
11.14
11.39
growth rate 0.0% 100.0% 70.2% -73.8% 120.5% -46.8% -42.2% 2.2%
ROA -66.02
106.84
-64.21
-90.03
15.99
8.59
36.61
15.61
15.83
10.58
9.53
growth rate 100.0% -100.0% 0.0% 100.0% -46.3% 326.2% -57.4% 1.4% -33.2% -9.9%
ROE 88.20
-245.90
-141.55
-202.72
37.92
14.74
58.73
24.95
30.81
21.57
18.94
growth rate -100.0% 0.0% 0.0% 100.0% -61.1% 298.4% -57.5% 23.5% -30.0% -12.2%
ROIC -73.66
-124.12
29.47
12.98
58.01
24.61
16.58
12.95
12.26
growth rate 0.0% 100.0% -56.0% 346.9% -57.6% -32.6% -21.9% -5.3%
Cur. Ratio 2.62
2.63
3.99
3.68
3.96
1.89
1.88
1.86
3.06
2.94
2.57
growth rate 0.4% 51.7% -7.8% 7.6% -52.3% -0.5% -1.1% 64.5% -3.9% -12.6%
Quick Ratio 2.16
2.59
3.88
3.32
3.33
1.57
1.63
1.67
2.84
2.71
2.30
growth rate 19.9% 49.8% -14.4% 0.3% -52.9% 3.8% 2.5% 70.1% -4.6% -15.1%
Leverage 5.69
1.63
3.32
1.93
1.59
1.61
1.59
2.16
1.95
2.02
growth rate -71.4% 103.7% -41.9% -17.6% 1.3% -1.2% 35.9% -9.7% 3.6%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 4.80
0.00
0.68
5.05
17.27
25.91
41.53
65.59
102.92
87.33
140.88
growth rate -100.0% 648.7% 241.7% 50.0% 60.3% 57.9% 56.9% -15.2% 61.3%
Acct.Payable 11.76
10.67
18.31
1.86
4.31
8.06
6.84
3.20
10.14
6.15
growth rate -9.3% 71.7% -89.8% 131.6% 86.7% -15.0% -53.3% 217.4% -39.4%
Cur.Assets 39.80
49.40
91.46
97.16
108.73
105.95
151.40
228.45
493.49
472.64
630.42
growth rate 24.1% 85.2% 6.2% 11.9% -2.6% 42.9% 50.9% 116.0% -4.2% 33.4%
Total Assets 47.00
53.73
93.99
111.00
136.78
188.63
309.57
424.46
977.81
1,160.28
1,504.10
growth rate 14.3% 74.9% 18.1% 23.2% 37.9% 64.1% 37.1% 130.4% 18.7% 29.6%
Cash 23.70
48.79
40.30
32.98
36.40
33.50
66.40
100.30
192.25
181.38
288.64
growth rate 105.9% -17.4% -18.2% 10.4% -8.0% 98.2% 51.1% 91.7% -5.7% 59.1%
Inventory 0.00
0.00
1.15
7.15
13.44
12.59
16.80
16.30
25.66
26.63
48.33
growth rate 520.8% 87.9% -6.4% 33.5% -3.0% 57.4% 3.8% 81.5%
Cur.Liabilities 15.20
18.77
22.98
26.40
28.12
56.93
80.74
123.00
161.35
160.59
245.11
growth rate 23.5% 22.5% 14.9% 6.5% 102.5% 41.8% 52.3% 31.2% -0.5% 52.6%
Liabilities 91.30
44.29
36.42
77.53
96.09
100.62
117.81
156.98
524.79
564.85
759.24
growth rate -51.5% -17.8% 112.9% 23.9% 4.7% 17.1% 33.3% 234.3% 7.6% 34.4%
LT Debt 75.00
22.71
11.34
47.04
26.22
7.09
4.17
329.46
345.17
361.75
growth rate -69.7% -50.1% 314.8% -44.3% -73.0% -41.2% 789.4% 4.8% 4.8%
Equity -44.32
9.44
57.57
33.46
40.70
88.01
191.76
267.48
453.02
595.43
744.86
growth rate 100.0% 509.7% -41.9% 21.6% 116.2% 117.9% 39.5% 69.4% 31.4% 25.1%
Common Shares 14.00
14.00
17.00
32.00
42.00
51.00
52.00
53.00
54.00
54.00
54.00
growth rate 0.0% 21.4% 88.2% 31.3% 21.4% 2.0% 1.9% 1.9% 0.0% 0.0%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 0.30
0.69
0.75
1.65
0.59
2.10
1.60
2.03
0.84
2.74
3.45
growth rate 128.3% 9.9% 118.6% -64.0% 254.8% -23.8% 26.6% -58.4% 224.2% 26.1%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA -32.55
-36.19
0.00
-24.50
34.52
66.81
114.64
128.99
143.13
138.40
growth rate 0.0% 0.0% 100.0% 93.5% 71.6% 12.5% 11.0% -3.3%
FCF per Share -2.75
-2.23
-0.28
0.86
0.58
1.92
2.43
2.44
2.70
growth rate 0.0% 0.0% 100.0% -32.6% 231.0% 26.6% 0.4% 10.7%
Sale Purchase of Stock 0.03
100.74
0.71
0.57
1.87
2.05
5.68
growth rate 347,262.1% -99.3% -19.6% 227.0% 9.9% 176.9%
FCF -33.00
-37.00
-48.00
-60.00
7.00
30.00
65.00
113.00
128.00
140.00
135.00
growth rate 0.0% 0.0% 0.0% 100.0% 328.6% 116.7% 73.9% 13.3% 9.4% -3.6%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 0.10
0.80
1.48
12.02
92.68
147.47
215.00
302.24
408.90
392.76
520.40
growth rate 703.0% 84.3% 712.1% 671.1% 59.1% 45.8% 40.6% 35.3% -4.0% 32.5%
Op.Income -40.10
-23.23
-46.28
-101.82
-5.28
20.84
54.22
99.54
144.44
150.27
188.10
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 160.1% 83.6% 45.1% 4.0% 25.2%
IBT -39.50
-39.47
-46.28
-92.27
-10.30
14.61
50.37
100.62
140.18
147.49
168.65
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 244.8% 99.8% 39.3% 5.2% 14.4%
Net Income -38.50
-23.23
-46.28
-101.82
-10.93
13.94
91.22
57.28
110.99
113.06
126.95
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 554.2% -37.2% 93.8% 1.9% 12.3%
EPS -3.02
3.64
-2.72
-2.90
-0.26
0.28
1.76
1.08
2.05
2.10
2.36
growth rate 100.0% -100.0% 0.0% 0.0% 100.0% 528.6% -38.6% 89.8% 2.4% 12.4%
Gross Profit 0.10
0.80
1.48
10.92
86.92
139.04
203.02
287.02
393.54
376.10
467.94
growth rate 703.0% 84.3% 637.5% 696.3% 60.0% 46.0% 41.4% 37.1% -4.4% 24.4%
R&D 35.10
30.63
23.52
17.25
19.59
29.14
42.79
49.58
89.21
69.10
75.96
growth rate -12.7% -23.2% -26.7% 13.6% 48.8% 46.9% 15.9% 79.9% -22.5% 9.9%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT 29.01
49.85
59.24
52.00
13.21
growth rate 71.8% 18.8% -12.2% -74.6%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 119.20
126.56
133.11
140.88
127.07
growth rate 6.2% 5.2% 5.8% -9.8%
Acct.Payable 3.12
5.52
11.19
6.15
5.95
growth rate 76.5% 103.0% -45.1% -3.1%
Cur.Assets 557.05
557.15
552.02
630.42
586.02
growth rate 0.0% -0.9% 14.2% -7.0%
Total Assets 1,189.87
1,491.02
1,510.02
1,504.10
1,507.44
growth rate 25.3% 1.3% -0.4% 0.2%
Cash 225.77
210.98
204.29
288.64
255.64
growth rate -6.6% -3.2% 41.3% -11.4%
Inventory 24.42
35.34
42.47
48.33
50.23
growth rate 44.7% 20.2% 13.8% 3.9%
Cur.Liabilities 168.34
269.28
299.61
245.11
240.81
growth rate 60.0% 11.3% -18.2% -1.8%
Liabilities 576.48
825.05
801.14
759.24
753.00
growth rate 43.1% -2.9% -5.2% -0.8%
LT Debt 349.23
353.35
357.52
361.75
366.04
growth rate 1.2% 1.2% 1.2% 1.2%
Equity 613.38
665.97
708.88
744.86
754.44
growth rate 8.6% 6.4% 5.1% 1.3%
Common Shares 0.05
0.05
0.05
0.05
0.05
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 2.54
0.54
0.16
0.22
growth rate -78.9% -69.7% 32.7%
Cash Dividends
growth rate
Cash From OA 8.92
91.95
5.60
31.93
36.20
growth rate 931.3% -93.9% 470.3% 13.4%
Sale Purchase of Stock
growth rate
FCF 6.38
91.42
5.44
31.72
growth rate 1,333.1% -94.1% 483.4%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 94.98
126.73
155.14
143.56
growth rate 33.4% 22.4% -7.5%
Op.Income 29.01
49.85
59.24
52.00
13.21
growth rate 71.8% 18.8% -12.2% -74.6%
IBT 29.03
47.21
52.71
39.69
10.93
growth rate 62.6% 11.7% -24.7% -72.5%
Net Income 21.52
34.67
40.00
30.77
5.69
growth rate 61.1% 15.4% -23.1% -81.5%
EPS
growth rate
Gross Profit 90.82
118.34
133.75
125.02
growth rate 30.3% 13.0% -6.5%
R&D 18.94
22.25
16.84
17.94
34.28
growth rate 17.5% -24.3% 6.5% 91.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (80.50)

YOY Growth Grade:

C (64.71)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 12.94 15.50 20.78
EPS / Growth 59.2% 2.07 1.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.7% 37.0% 37.2%
Future PE 3.38 18.16 36.01
Future EPS 2.45 48.07 48.78
Value Price
MOS %
2.05
-93.6%
215.84
572.6%
434.22
1,253.1%
MOS Price 1.02 107.92 217.11
IRT 13.68 5.20 5.19

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.